Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV- 368 plus Tilsotolimod in Subjects with Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma study (Abbvie M19-894)

Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV- 368 plus Tilsotolimod in Subjects with Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma study (Abbvie M19-894)

Trial Category:
Head and Neck
Phase
I
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members